Hair loss treatments in development

How it works: Red/near-infrared light delivered via combs, caps, bands, or in-clinic panels to the scalp, hypothesized to stimulate mitochondrial activity in follicle cells and prolong the growth phase.

Developer

Multiple device makers (HairMax, Theradome, Capillus, iRestore, and others)

Stage

Approved — multiple FDA-cleared devices already on the market (510(k) clearance, not a 'novel drug' approval)

Latest (N/A — ongoing/established category, no single 2025-2026 dated event found)

LLLT remains one of only three FDA-cleared approaches for AGA (alongside minoxidil and finasteride); HairMax has accumulated 8 FDA clearances across its device line. No major new clearance specific to 2025-2026 was identified in this research pass beyond ongoing device iterations.

Results so far

Evidence base is a mix of device-specific clinical studies submitted for 510(k) clearance; this research pass did not pull a consolidated, dated efficacy figure and instead found general claims of being 'FDA-cleared' from secondary device-marketing-adjacent sources.

What's next

N/A — mature, already-marketed device category.

In India

Not specifically assessed; LLLT devices are sold/imported into India via e-commerce, but Indian-specific regulatory (CDSCO medical device) status was not verified in this research pass.

Sources: Company announcement ↗ · Company announcement ↗ · Trial registry ↗

How it works: 5-alpha-reductase inhibitor applied directly to the scalp to lower local DHT with the goal of less systemic absorption/side effects than oral finasteride.

Developer

Multiple compounding pharmacies / telehealth platforms (US); standardized sprays in some European countries

Stage

Not FDA approved in the US (compounded only); approved/authorized topical finasteride sprays exist in multiple European countries since 2020

Latest (Apr 2025)

FDA issued a warning in April 2025 about compounded topical finasteride, citing 32 reported adverse-event cases (including low libido and erectile dysfunction) between 2019-2024.

Results so far

No pivotal US trial data cited; European standardized formulations have 'substantial randomized clinical trial evidence' per secondary sources, but no specific numeric result was verified in this research pass.

What's next

No FDA approval timeline exists because no sponsor has an active NDA for topical finasteride identified in this research.

In India

Not specifically assessed for CDSCO status; topical finasteride is informally available via some Indian compounding/telehealth channels but this was not independently verified in this research pass.

Sources: News report ↗ · Journal paper ↗ · Journal paper ↗

How it works: Botulinum toxin injected into the scalp, hypothesized to relax scalp muscle tension (improving blood flow/oxygenation to follicles) and to have direct anti-inflammatory/anti-apoptotic effects on dermal papilla cells.

Developer

No single commercial sponsor — an off-label procedure performed by dermatologists/cosmetic clinics using existing approved botulinum toxin products

Stage

Procedure in off-label clinical use; evidence base is mixed small RCTs, not an approved indication

Latest (2026 (systematic review); underlying trial dates mixed (2024-2025))

A 2026 systematic review (Dermatologic Therapy/Wiley) and several small randomized trials show conflicting results: some trials report increased hair density (13-20%) over 12-24 weeks, while a separate triple-blind, placebo-controlled JAAD trial found botulinum toxin did NOT improve hair regrowth and that terminal hair density actually decreased in the treated areas.

Results so far

Evidence is genuinely mixed: some studies report +13-20% hair density gains and improved follicle diameter with no major adverse effects; a triple-blind RCT published in JAAD found no benefit and a decrease in terminal hair density. No consensus efficacy figure exists.

What's next

Not on a path to a formal drug-style approval since it uses existing approved toxin products off-label for a cosmetic/dermatologic procedure; further trials are ongoing (e.g., a trial comparing botulinum toxin A vs nanofat is slated to start December 2026).

In India

Not specifically assessed; botulinum toxin is already widely available in India for its approved cosmetic/medical indications, so off-label scalp use for hair loss is plausible but was not verified in this research pass.

Sources: Journal paper ↗ · Journal paper ↗ · Journal paper ↗ · Trial registry ↗

How it works: Oral vasodilator (repurposed blood-pressure drug) taken at low doses to stimulate hair growth, thought to work via vasodilation and prolonging the anagen phase.

Developer

Off-label generic use; no single commercial sponsor. A Phase 3 trial of an oral minoxidil product (N1087) in men was registered in 2026.

Stage

Widely used off-label; formal Phase 3 trial (N1087) newly registered

Latest (Apr 2026)

A Phase 3 trial (NCT07529977) evaluating oral minoxidil (N1087) vs placebo in men with AGA was posted to ClinicalTrials.gov in April 2026. Separately, a 2026 patient survey found unwanted hair growth (hypertrichosis) in 71.6% of women on LDOM.

Results so far

Reported adverse-effect rates: dose-dependent hypertrichosis ~24%, transient shedding 16-22%, mild peripheral edema ~2%; serious complications (e.g., pericardial effusion) rare at alopecia doses. International Delphi consensus dosing: 1.25 mg/day starting dose for women, 2.5 mg/day for men.

What's next

No approval pathway exists yet for a branded low-dose oral minoxidil product for hair loss; use remains off-label pending outcome of trials like N1087.

In India

No India-specific trial identified; oral minoxidil is already widely prescribed off-label in India as elsewhere, but this was not independently confirmed with an Indian source.

Sources: Trial registry ↗ · Journal paper ↗ · Journal paper ↗ · Journal paper ↗

How it works: Topical anti-androgen (same active ingredient as acne drug Winlevi) that blocks androgen receptors in the scalp to reduce DHT-driven follicle miniaturization.

Developer

Cosmo Pharmaceuticals (Cassiopea)

Stage

Phase 3 completed (two pivotal trials, SCALP1/SCALP2); not yet filed

Latest (Dec 2025)

Cosmo announced positive topline Phase 3 results from two trials (1,465 patients, US and Europe) in December 2025; company plans an FDA NDA filing in early 2027 and an EU MAA filing.

Results so far

One trial: 539% relative improvement in target-area hair count vs vehicle; second trial: 168% relative improvement; pooled analysis >252% improvement (p<0.05). Treatment-emergent adverse events: 5.1% clascoterone vs 6.1% placebo. Patient-reported outcomes significant in one trial, a positive trend in the other.

What's next

NDA filing planned for early 2027; given typical FDA review timelines, approval (if any) unlikely before 2028.

In India

No India-specific trial or filing identified. Company statements say this could be the first new AGA mechanism in >30 years if approved in US/EU.

Sources: News report ↗ · News report ↗ · Company announcement ↗

How it works: Topical androgen receptor antagonist applied to the scalp to block DHT signalling locally without significant systemic absorption.

Developer

Kintor Pharmaceutical (China)

Stage

Phase 3 completed in China (pivotal trial); not approved anywhere yet

Latest (Mar 2026)

Kintor's March 2026 annual-results disclosure reported topline data from the 666-patient Phase 3 stage of its China pivotal trial; company says it will file an NDA with China's NMPA soon.

Results so far

Target area hair count improved 15.33 hairs/cm2 (1.0% dose) and 14.46 hairs/cm2 (0.5% dose) vs 4.68 hairs/cm2 for placebo; no drug-related serious adverse events reported (press-release figures, not yet in a peer-reviewed paper).

What's next

NDA filing with China's NMPA described as imminent as of early 2026; no FDA filing announced.

In India

No India-specific development or CDSCO filing identified in this research.

Sources: News report ↗ · News report ↗ · Trial registry ↗ · Trial registry ↗

How it works: Topical first-in-class androgen receptor PROTAC (proteolysis-targeting chimera) that degrades the androgen receptor locally in scalp skin rather than just blocking it.

Developer

Kintor Pharmaceutical (China)

Stage

Phase 2 completed (met primary endpoint); Phase 2b/3 planned in China

Latest (Dec 2025)

Kintor reported Phase 2 topline data (180 male AGA patients, QD and BIW dosing arms) showing statistically significant hair-count gains vs placebo, and said it plans to start a Phase 2b/3 trial in China.

Results so far

0.5% QD arm: +16.80 hairs/cm2; 1% BIW arm: +11.94 hairs/cm2, both significant vs placebo; adverse event rate comparable to placebo with no reported adverse sexual events (press-release data).

What's next

Phase 2b/3 initiation in China targeted for 2026 per company statements; no global/FDA timeline given.

In India

No India-specific development identified.

Sources: News report ↗ · Trial registry ↗ · Company announcement ↗ · News report ↗

How it works: Monoclonal antibody against the prolactin receptor (PRLR); blocking PRLR signalling is hypothesized to relieve prolactin-driven suppression of hair follicles.

Developer

Hope Medicine (Nanjing) / originally Bayer (as BAY-1158061)

Stage

Phase 1b completed; Phase 2 ongoing (FDA clearance obtained, 180-participant trial)

Latest (2025 (per Hope Medicine company release referenced in search; exact day not captured))

Hope Medicine received US FDA clearance to begin a Phase 2 trial (180 participants, HMI-115 vs placebo over 24 weeks) after positive Phase 1b results.

Results so far

Phase 1b: average non-vellus target area hair count increased by 14 hairs/cm2 from baseline in two male patients; drug reported safe and well tolerated. Note the very small n reported in the search summary.

What's next

Phase 2 enrollment underway as of research date; no Phase 3/filing timeline publicly stated.

In India

No India-specific development identified.

Sources: News report ↗ · Company announcement ↗ · News report ↗

How it works: Topical small molecule designed to reactivate dormant hair follicle stem cells and push them into the growth (anagen) phase, a regenerative rather than hormone-blocking approach.

Developer

Pelage Pharmaceuticals

Stage

Phase 2a completed; Phase 3 planned to start 2026

Latest (Jun 2025)

Pelage announced positive Phase 2a results in June 2025 (78 men and women, 4 weeks of daily dosing, 12-week follow-up) and a $120M Series B (Oct 2025, co-led by ARCH Venture Partners and GV/Google Ventures) to fund Phase 3.

Results so far

Met primary safety/efficacy endpoints with no systemic absorption; 31% of men showed >20% increase in hair density, including new growth in previously bald areas (press-release figures).

What's next

Phase 3 studies planned to begin in 2026.

In India

No India-specific development identified.

Sources: Company announcement ↗ · News report ↗ · Company announcement ↗ · News report ↗

How it works: Topical small molecule intended to activate dormant hair follicle stem cells and induce the anagen (growth) phase, similar regenerative rationale to PP405.

Developer

Technoderma Medicines

Stage

Phase 2a completed

Latest (2024 (per PRNewswire release referenced in 2025-2026 coverage; exact 2026 follow-up not found))

Technoderma reported Phase 2a results via press release/PRNewswire describing a 4-month, 71-participant, 1:1:1 randomized trial comparing two concentrations to placebo.

Results so far

Non-vellus target area hair count increased by 24.3 hairs (0.02% dose) and 20.3 hairs (0.0025% dose) vs 14 hairs for placebo; well tolerated with minimal to no systemic exposure (press-release figures).

What's next

No publicly stated Phase 3 timeline found in this research pass.

In India

No India-specific development identified.

Sources: Company announcement ↗ · News report ↗ · Trial registry ↗

How it works: Extracellular vesicles ('exosomes') secreted by stem cells (often hair-follicle or other mesenchymal stem cells), injected into the scalp to deliver growth-promoting signals to miniaturized follicles.

Developer

Multiple small clinics/early-stage sponsors; no single dominant commercial developer identified

Stage

Early clinical (small trials/case series); already offered commercially in some clinics ahead of large-scale regulatory evidence

Latest (May 2026)

A May 2025 systematic review identified 11 clinical studies (including 2 RCTs) on exosome-based hair-loss interventions; one registered RCT (NCT06932393) was terminated in May 2026 due to the trial site's regulatory ineligibility.

Results so far

Across reviewed studies, hair count improvements ranged from 9.5 to 35 new hairs/cm2 and hair thickness improved by up to 13 micrometers after 1-2 sessions, with no serious adverse effects reported — but the review explicitly calls for larger, better-designed trials before broad clinical adoption.

What's next

No regulatory approval pathway established; this remains a procedure offered off-label/as an aesthetic service in many markets rather than an approved drug.

In India

Not specifically assessed; exosome/PRP-adjacent treatments are known to be offered in some Indian hair clinics commercially, but no Indian trial or regulatory status was verified in this research pass.

Sources: Journal paper ↗ · Trial registry ↗ · Journal paper ↗

How it works: A naturally occurring sugar formulated into a topical alginate hydrogel; proposed to upregulate VEGF (a blood-vessel-growth signal) in scalp skin to stimulate hair follicles, similar in concept to how minoxidil and PRP are thought to work.

Developer

Academic research group (mechanism paper); a human trial (NCT07502976) has since been registered

Stage

Preclinical (mouse model) with a human trial now registered on ClinicalTrials.gov

Latest (2024 (mouse study); trial registration date for NCT07502976 not individually confirmed)

A preclinical paper (PMC11180715) showed 2dDR hydrogel stimulated hair regrowth in a mouse AGA model at 80-90% of the effect of minoxidil; a human trial, 'Topical 2-Deoxy-D-ribose Hydrogel Versus Minoxidil 5% Solution for Androgenetic Alopecia' (NCT07502976), has since been registered on ClinicalTrials.gov.

Results so far

Mouse model: increased hair follicle density, anagen:telogen ratio, follicle diameter, and vascularization, with effects described as comparable (80-90%) to minoxidil — this is animal data only, no human efficacy data yet.

What's next

Human trial (NCT07502976) appears newly registered; no results or completion date were verified in this research pass.

In India

No India-specific development identified.

Sources: Journal paper ↗ · Trial registry ↗

How it works: Lab-grown dermal papilla cells (the signalling cells at the base of hair follicles), or their secreted factors ('secretome'/conditioned media), injected or applied to reawaken miniaturized follicles and induce new hair growth.

Developer

Multiple academic/early-stage groups (e.g., hiPSC-DPC secretome research; HFDPC spheroid injection research); no single lead commercial sponsor identified

Stage

Preclinical (mouse/spheroid models) and very early research-stage

Latest (Aug 2026)

2025-2026 peer-reviewed research described protocols for generating hiPSC-derived dermal papilla cells and testing their conditioned medium as a cell-free regenerative therapy, and for fabricating small dermal-papilla-cell spheroids that induced hair shaft formation when injected into nude mice.

Results so far

No human efficacy data — results are limited to animal (nude mouse) and in-vitro models.

What's next

No human trial timeline publicly stated for these specific academic programs.

In India

A separate, unrelated allogenic mesenchymal stem cell (MSC) trial for AGA was identified as being run by the National Institute of Blood and Marrow Transplant in Pakistan (not India) — included here only to flag it is NOT an Indian trial, despite regional proximity.

Sources: Journal paper ↗ · Journal paper ↗ · Trial registry ↗

How it works: An existing FDA-approved drug (for macular degeneration) being investigated off-label/preclinically as a YAP inhibitor; inhibiting the Hippo/YAP pathway has been linked in mouse studies to activating Wnt-pathway hair-follicle regeneration and reducing scarring, including around hair transplant sites.

Developer

Academic research groups; no single commercial sponsor identified for a hair-loss indication

Stage

Preclinical / early research only — verteporfin itself is an approved drug for a different (ophthalmic) indication, but has no approval or trial completion for hair loss

Latest (Mar 2025)

A 2025 study (FASEB BioAdvances) found that verteporfin inhibition of the Hippo pathway actually reduced proliferation and stemness of hair-follicle neural crest stem cells under hypoxia — a nuanced/mixed finding, alongside separate research suggesting YAP inhibition can promote hair follicle regeneration via Trps1/Wnt signalling and reduce transplant-related scarring.

Results so far

Findings are mixed and context-dependent across different stem cell populations and models; no consolidated single 'key result' can be stated — this is an active, unsettled area of preclinical research, not a therapy ready for trials.

What's next

No human trial or timeline identified.

In India

No India-specific development identified.

Sources: Journal paper ↗ · Journal paper ↗ · Journal paper ↗

How it works: Oral JAK1/JAK2 inhibitor; dampens the autoimmune inflammatory signalling that attacks hair follicles in alopecia areata.

Developer

Eli Lilly / Incyte

Stage

Approved — USA (adults, June 2022; adolescents 12+, September 2026)

Latest (Sept 2026)

FDA expanded the US approval of baricitinib to adolescents aged 12 and older with severe alopecia areata in September 2026.

Results so far

No new efficacy numbers captured in this pass beyond the original adult pivotal trials (BRAVE-AA1/AA2); adolescent approval was based on pediatric extrapolation/trial data not independently reviewed here.

What's next

Already approved in the US (and other markets for the original rheumatoid-arthritis/other indications); alopecia-specific indication expansion to adolescents is the latest milestone.

In India

Generic baricitinib (e.g., Natco Pharma's 'Barinat') is sold in India, but this appears to be for baricitinib's other approved indications (e.g., rheumatoid arthritis/COVID) rather than a confirmed CDSCO approval for alopecia areata specifically — the alopecia-areata indication in India could not be confirmed in this research pass and should be treated as unverified/likely off-label if used.

Sources: News report ↗ · Regulator ↗ · Company announcement ↗ · News report ↗

How it works: Oral selective JAK1/JAK2 inhibitor that dampens the autoimmune attack on hair follicles underlying alopecia areata.

Developer

Originally Concert Pharmaceuticals; acquired by Sun Pharmaceutical Industries (India-headquartered) in March 2023

Stage

Approved — USA (July 2024); UK (March 2026)

Latest (2026 (EADV Congress; exact date within the conference not captured))

Two-year open-label extension data presented at EADV Congress 2026 showed sustained efficacy and a safety profile consistent with prior experience through up to two years of treatment at the approved 8 mg twice-daily dose; no deaths, thrombosis, or major adverse cardiovascular events reported in that cohort. UK (MHRA) approval for severe AA followed in March 2026.

Results so far

Durable scalp hair regrowth maintained through Week 108 in the European open-label extension; most treatment-emergent adverse events mild/moderate, discontinuations for AEs uncommon.

What's next

Already approved and commercially launched in the US (July 2025 launch) and newly approved in the UK (March 2026); no additional approvals announced elsewhere.

In India

Owned globally by Sun Pharma (an Indian company) but as of this research pass, Leqselvi has not been launched or approved in India — searches found no CDSCO filing or Indian launch announcement.

Sources: Company announcement ↗ · News report ↗ · Regulator ↗ · Company announcement ↗ · Company announcement ↗

How it works: Oral JAK3/TEC family kinase inhibitor that blocks signalling pathways involved in the immune attack on hair follicles in alopecia areata.

Developer

Pfizer

Stage

Approved — USA (June 2023), for ages 12+

Latest (2025 (EADV Congress))

Three-year data from the ALLEGRO-2b/3 long-term extension, presented at EADV 2025, showed about 90% of patients who reached SALT score <=20 at 12 months maintained that response through 3 years, with roughly 30% achieving complete scalp regrowth; separate analyses reported reduced psychosocial burden by week 48 at the 50 mg dose.

Results so far

65.1% of patients maintained SALT score <=20 at 36-38 months; of those who hit that threshold at 12 months, ~90% sustained it to 3 years.

What's next

Already approved in the US; long-term-extension data continuing to read out through 2025-2026. No specific India regulatory timeline found.

In India

No CDSCO approval or Indian launch/trial found in this research pass.

Sources: News report ↗ · News report ↗ · Journal paper ↗ · Journal paper ↗

How it works: Oral selective JAK1 inhibitor that suppresses the immune signalling (interferon-gamma/other cytokines) driving follicle attack in alopecia areata.

Developer

AbbVie

Stage

Approved in EU; FDA application submitted (not yet approved in US as of April 2026)

Latest (Apr 2026)

AbbVie submitted an FDA application for upadacitinib in severe alopecia areata (adults and adolescents) in April 2026, based on the Phase 3 UP-AA program (two trials, 1,399 participants total); the EU had already approved it for severe alopecia.

Results so far

Study 1: 45.2% (15 mg) and 55.0% (30 mg) of patients reached SALT<=20 at week 24 (vs placebo, exact placebo % not captured for Study 1). Study 2: 44.6% (15 mg) and 54.3% (30 mg) reached SALT<=20 at week 24 vs 3.4% placebo. Upadacitinib was the first JAK inhibitor reported to meet the ranked secondary endpoint of complete scalp regrowth (SALT=0) at week 24.

What's next

FDA decision pending as of October 2026 following the April 2026 submission; EU already approved.

In India

No India-specific approval or filing identified.

Sources: Company announcement ↗ · Company announcement ↗ · Company announcement ↗ · News report ↗

How it works: Fully human anti-IL-7 receptor-alpha monoclonal antibody that blocks IL-7 and TSLP signalling to re-regulate the adaptive immune cells attacking hair follicles.

Developer

Q32 Bio

Stage

Phase 2 (SIGNAL-AA) completed Part B; registration-directed program planned

Latest (2026 (late-breaking EADV 2026 presentation referenced; exact date not captured))

Q32 Bio announced positive 36-week topline results from Part B of the Phase 2 SIGNAL-AA trial in severe-to-very-severe AA, and said it plans to advance bempikibart into a registration-directed program in the first half of 2027; the drug has FDA Fast Track designation.

Results so far

Specific numeric efficacy figures for the 36-week Part B readout were not captured in the search snippets reviewed — flagged as needing direct verification from the primary press release before quoting numbers.

What's next

Registration-directed (pivotal) program targeted to begin H1 2027.

In India

No India-specific development identified.

Sources: News report ↗ · Regulator ↗ · Company announcement ↗ · Trial registry ↗

How it works: Engineered IL-2 variant ('IL-2 mutein') designed to selectively expand regulatory T cells to restore immune tolerance and stop the autoimmune attack on hair follicles.

Developer

Nektar Therapeutics

Stage

Phase 2b (REZOLVE-AA) topline reported

Latest (Dec 2025)

Nektar released topline Phase 2b REZOLVE-AA results (92 patients with severe-to-very-severe AA) in December 2025, describing a 'meaningful level of clinical effect'; full data planned for presentation at a 2026 medical conference, with 16-week extension data expected early Q2 2026.

Results so far

Specific response-rate numbers were not captured in the search snippets reviewed (only qualitative 'meaningful clinical effect' language) — flag for verification against Nektar's primary IR release before quoting figures.

What's next

Full data presentation expected at a medical conference in 2026; next clinical step (Phase 3) not yet announced in sources reviewed.

In India

No India-specific development identified.

Sources: Company announcement ↗ · News report ↗ · News report ↗